Nanologica’s patented technology platform, NLAB Silica™, enables the use of mesoporous silica for tailor-made drug delivery systems for enhanced bioavailability and controlled release. The technology has been applied to many projects in both research and commercial collaborations, validating Nanologica’s concepts of how silica-based drug delivery systems can add value to the pharmaceutical product.
NLAB Silica™ particles solves problems in pharmaceutical formulations by improving solubility, enhancing bioavailability and protecting APIs from degradation.
Graph: Reformulation of the HIV drug Atazanavir (ATV) using NLAB Silica™ for improved bioavailability in vivo
If you would like to know more about Nanologica’s drug delivery technology, please contact Adam Feiler, CTO adam.feiler@nanologica.com.
For more information:
• Enhancing dissolution kinetics of poorly soluble compounds
• Controlling release kinetics
• Improving bioavailability
• Stabilizing amorphous form
• Improving handling of APIs
• Applicable for a broad range of APIs
• Nanoporous amorphous silica
• GRAS approved excipient
• Tuneable particle and pore size
• High loading up to 50%
• Free-flowing powder
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.